Asymmetric dimethylarginine (ADMA): The silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule

European Journal of Clinical Investigation

Volumn 35, Issue 2, 2005, Pages 71-79

  Fliser, Danilo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Asymmetric dimethylarginine; Atherosclerosis; Cardiovascular risk; Dimethylarginine dimethylaminohydrolase; Nitric oxide; Renal dysfunction

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ARGININE; DIMETHYLARGININASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; UREMIC TOXIN;

AGING; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR RISK; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; STROKE; SYSTEMIC VASCULAR RESISTANCE; VOLUNTEER;

AMIDOHYDROLASES; ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY DISEASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RISK FACTORS; UREMIA;

EID: 13544253367     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01457.x     Document Type: Review

References (111)

1. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004;109 (Suppl. 1):II27-II33.
2. Moncada S, Higgs A. The 1-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
3. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
4. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000;101:948-54.
5. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003;41:1769-75.
6. Cooke JP. Asymmetrical dimethylarginine - the über marker? Circulation 2004;109:1813-8.
7. Fliser D, Kielstein JT, Bode-Böger SM, Haller H. Asymmetric dimethylarginine (ADMA): a cardiovascular risk factor in patients with renal disease? Kidney Int 2003;63 (Suppl. 84):S37-S40.
8. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
9. Najbauer J, Johnson BA, Young AL, Aswad DW. Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase (s) modifying arginine in numerous proteins. J Biol Chem 1993;268:10501-9.
10. Tang J, Kao PN, Herschman HR. Protein-arginine methyltransferase I, the predominant protein-arginine methyltransferase in cells, interacts with and is regulated by interleukin enhancer-binding factor 3. J Biol Chem 2000;275:19866-76.
11. MacAllister RJ, Fickling SA, Whitley GS, Vallance P. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994;112:43-8.
12. Lee JH, Cook JR, Yang ZH, Mirochnitchenko O, Gunderson S, Felix AM et al. PRMT7: A new protein arginine methyltransferase that synthesizes symmetric dimethylarginine. J Biol Chem 2004 October 19 [Epub ahead of print].
13. Faraci FM, Brian JE Jr, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995;269:H1522-7.
14. Segarra G, Medina P, Ballester RM, Lluch P, Aldasoro M, Vila JM et al. Effects of some guanidino compounds on human cerebral arteries. Stroke 1999;30:2206-10.
15. Segarra G, Medina P, Vila JM, Chuan P, Domenech C, Torondel B et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens 2001;14:1142-8.
16. Gardiner SM, Kemp PA, Bennett T, Palmer RM, Moncada S. Regional and cardiac haemodynamic effects of NG, NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol 1993;110:1457-64.
17. Jin JS, D'Alecy LG. Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J Cardiovasc Pharmacol 1996;28:439-46.
18. Xiao S, Wagner L, Schmidt RJ, Baylis C. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int 2001;59:1466-72.
19. Chan JR, Boger RH, Bode-Boger SM, Tangphao O, Tsao PS, Blaschke TF et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 2000;20:1040-6.
20. Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993;7:193-4.
21. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC et al. Cardiovascular effects of systemic NO synthase inhibition with asymmetric dimethylarginine in humans. Circulation 2004;109:172-7.
22. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23:1455-9.
23. Kielstein JT, Simmel S, Bode-Boger SM, Roth HJ, Schmidt-Gayk H, Haller H et al. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res 2004, 27, 143-7.
24. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996;11:2449-52.
25. Anderstam B, Katzarski K, Bergstrom J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997;8:1437-42.
26. Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;10:594-600.
27. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-7.
28. Kielstein JT, Boger RH, Bode-Boger SM, Martens-Lobenhoffer J, Lonnemann G, Frolich JC et al. Low dialysance of asymmetric dimethylarginine (ADMA) - in vivo and in vitro evidence of significant protein binding. Clin Nephrol 2004;62:295-300.
29. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002;13:490-6.
30. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002;62:339-45.
31. Mallamaci F, Tripepi G, Maas R, Malatino L, Boger R, Zoccali C. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol 2004;15:435-41.
32. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:170-6.
33. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deaminases. Biochem J 1999;343:209-14.
34. Murray-Rust J, Leiper J, McAlister M, Phelan J, Tilley S, Santa Maria J et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 2001;8:679-83.
35. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997;52:1593-601.
36. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002;99:13527-32.
37. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, Oberhollenzer F et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001;103:1064-70.
38. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002;105:15-21.
39. Nijveldt RJ, Van Leeuwen PA, Van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 2002;17:1999-2002.
40. Nijveldt RJ, Teerlink T, van Guldener C, Prins HA, van Lambalgen AA, Stehouwer CD et al. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol Dial Transplant 2003;18:2542-50.
41. Kielstein JT, Frolich JC, Haller H, Fliser D. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrol Dial Transplant 2001;16:1742-5.
42. Pinkau T, Hilgers KF, Veelken R, Mann JF. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? J Am Soc Nephrol 2004;15:517-23.
43. Wagner L, Riggleman A, Erdely A, Couser W, Baylis C. Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis. Kidney Int 2002;62:532-6.
44. Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 2003;107:1891-5.
45. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141-6.
46. Xiong Y, Yuan LW, Deng HW, Li YJ, Chen BM. Elevated serum endogenous inhibitor of nitric oxide synthase and endothelial dysfunction in aged rats. Clin Exp Pharmacol Physiol 2001;28:842-7.
47. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 2000;101:856-61.
48. Scuteri A, Stuehlinger MC, Cooke JP, Wright JG, Lakatta EG, Anderson DE et al. Nitric oxide inhibition as a mechanism for blood pressure increase during salt loading in normotensive postmenopausal women. J Hypertens 2003;21:1339-46.
49. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003;42:985-90.
50. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-7.
51. Paiva H, Laakso J, Laine H, Laaksonen R, Knuuti J, Raitakari OT. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol 2002;40:1241-7.
52. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-5.
53. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:1557-64.
54. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B et al. LDL cholesterol up-regulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87:99-105.
55. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000;20:2039-44.
56. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001;38:111-6.
57. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O et al. Endothelial dysfunction induced by hyperhomocyst (e) inemia: role of asymmetric dimethylarginine. Circulation 2003;108:933-8.
58. Sydow K, Hornig B, Arakawa N, Bode-Boger SM, Tsikas D, Munzel T et al. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Vasc Med 2004;9:93-101.
59. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569-75.
60. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420-6.
61. Masuda H, Goto M, Tamaoki S, Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol 1999;126:211-8.
62. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997;15:901-9.
63. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999;33:652-8.
64. Takiuchi S, Fujii H, Kamide K, Horio T, Nakatani S, Hiuge A et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens 2004;17:802-8.
65. Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997;29:242-7.
66. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 2001;37:489-92.
67. Kielstein JT, Bode-Böger SM, Martens-Lobenhoffer J, Hesse G, Gatzke R, Tacacs A et al. Asymmetric dimethylarginine (ADMA), pulmonary hemodynamic indices, and survival in patients with primary pulmonary hypertension. (Submitted).
68. Arrigoni FI, Vallance P, Haworth SG, Leiper JM. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 2003;107:1195-201.
69. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-8.
70. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003;24:1912-9.
71. Lu TM, Ding YA, Charng MJ, Lin SJ. Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol 2003;26:458-64.
72. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004;27:765-9.
73. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-74.
74. Yoo JH, Lee SC. Elevated levels of plasma homocyst (e) ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001;158:425-30.
75. Rajagopalan S, Pfenninger D, Kehrer C, Chakrabarti A, Somers E, Pavlic R et al. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum 2003;48:1992-2000.
76. Hori T, Matsubara T, Ishibashi T, Ozaki K, Tsuchida K, Mezaki T et al. Significance of asymmetric dimethylarginine (ADMA) concentrations during coronary circulation in patients with vasospastic angina. Circ J 2003;67:305-11.
77. Jang JJ, Ho HK, Kwan HH, Fajardo LF, Cooke JP. Angiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine. Circulation 2000;102:1414-9.
78. Kielstein JT, Bode-Boger SM, Klein G, Graf S, Haller H, Fliser D. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest 2003;33:370-5.
79. Saitoh M, Osanai T, Kamada T, Matsunaga T, Ishizaka H, Hanada H et al. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels 2003;18:177-82.
80. Feng Q, Lu X, Fortin AJ, Pettersson A, Hedner T, Kline RL et al. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure. Cardiovasc Res 1998;37:667-75.
81. Sawidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003;361:1511-7.
82. Mittermayer F, Mayer BX, Meyer A, Winzer C, Pacini G, Wagner OF et al. Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women with previous gestational diabetes. Diabetologia 2002;45:1372-8.
83. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002;106:987-92.
84. Xiong Y, Fu YF, Fu SH, Zhou HH. Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes. J Cardiovasc Pharmacol 2003;42:191-6.
85. Hermenegildo C, Medina P, Peiro M, Segarra G, Vila JM, Onega J et al. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients. J Clin Endocrinol Metab 2002;87:5636-40.
86. Weis M, Kledal TN, Lin KY, Panchal SN, Gao SZ, Valantine HA et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation 2004;109:500-5.
87. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morirnatsu M et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 2003;92:226-33.
88. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003;108:3042-7.
89. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-30.
90. Smirnova IV, Kajstura M, Sawamura T, Goligorsky MS. Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. Am J Physiol Heart Circ Physiol 2004;287:H782-90.
91. Scalera F, Borlak J, Beckmann B, Martens-Lobenhoffer J, Thum T, Tager M et al. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl 1-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol 2004;24:1816-22.
92. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004;24:1682-8.
93. Jones LC, Tran CT, Leiper JM, Hingorani AD, Vallance P. Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun 2003;310:836-43.
94. Boger RH, Bode-Boger SM, Brandes RP, Phivthong-ngam L, Bohme M, Nafe R et al. Dietary 1-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997;96:1282-90.
95. Boger RH, Bode-Boger SM, Thiele W, Creutzig A, Alexander K, Frolich JC. Restoring vascular nitric oxide formation by 1-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998;32:1336-44.
96. Piatti P, Fragasso G, Monti LD, Setola E, Lucotti P, Fermo I et al. Acute intravenous 1-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation 2003;107:429-36.
97. Walker HA, McGing E, Fisher I, Boger RH, Bode-Boger SM, Jackson G et al. Endothelium-dependent vasodilation is independent of the plasma 1-arginine/ADMA ratio in men with stable angina: lack of effect of oral 1-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 2001;38:499-505.
98. Teerlink T, Neele SJ, de Jong S, Netelenbos JC, Stehouwer CD. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) 2003;105:67-71.
99. Holden DP, Cartwright JE, Nussey SS, Whitley GS. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation 2003;108:1575-80.
100. Post MS, Verhoeven MO, van der Mooren MJ, Kenemans P, Stehouwer CD, Teerlink T. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab 2003;88:4221-6.
101. Jiang JL, Li Ns NS, Li YJ, Deng HW. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 2002;135:1175-82.
102. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004;94:157-61.
103. Jiang JL, Jiang DJ, Tang YH, Li NS, Deng HW, Li YJ. Effect of simvastatin on endothelium-dependent vaso-relaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol Sin 2004;25:893-901.
104. Pereira EC, Bertolami MC, Faludi AA, Salem M, Bersch D, Abdalla DS. Effects of simvastatin and 1-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects. Free Radic Res 2003;37:529-36.
105. Paiva H, Laakso J, Lehtimaki T, Isomustajarvi M, Ruokonen I, Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003;41:219-22.
106. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects Pravastatin Atherosclerosis 2003;166:279-84.
107. Dierkes J, Westphal S, Martens-Lobenhoffer J, Luley C, Bode-Boger SM. Fenofibrate increases the 1-arginine. ADMA ratio by increase of 1-arginine concentration but has no effect on ADMA concentration. Atherosclerosis 2004;173:239-44.
108. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin- converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002;90:974-82.
109. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N (G), N (G) -dimethylarginine in human essential hypertension. Am J Hypertens 2002;15:590-3.
110. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra) renal vascular resistance in patients with type 2 diabetes mellitus (in revision).
111. Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002;51:843-6.